INA

Across TCGA pan-cancer cohorts, INA mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated INA data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher INA mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated INA expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, LUAD, and UCEC are the cancer types where INA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	III,IV	0.878	0.305	<.001	66	view →
LUAD	DFS	Median	All	0.433	0.818	.018	5	view →
UCEC	DFS	Median	II,III,IV	0.847	0.490	.042	4	view →
CCRCC	DFS	Tertile	III,IV	0.318	1.000	.049	3	view →
GBM	OS	Median	All	0.305	0.435	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

INA–PDAC (DFS)

Open the PDAC breakdown →